(161 days)
Not Found
Yes
The device description explicitly states that the software uses "artificial intelligence algorithm" and "deep learning techniques" to analyze chest x-rays.
No
The device aids in the assessment of pneumothorax by identifying suspected findings and prioritizing cases, but it does not directly treat or cure any condition. It is a diagnostic/triage tool, not a therapeutic one.
No.
The device is described as a "software workflow tool" and a "radiological computer-assisted triage and notification software system" intended to aid in the clinical assessment and prioritize worklists for features suggestive of pneumothorax. It is explicitly stated that "Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out pneumothorax or otherwise preclude clinical assessment of X-Ray cases." This indicates it does not provide a definitive diagnosis.
Yes
The device is explicitly described as a "software workflow tool" and a "radiological computer-assisted triage and notification software system." While it requires installation on a server and integration with existing IT systems (PACS/workstation), these are deployment environments and not hardware components included as part of the device itself. The core functionality is software-based analysis and notification.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device function: The EFAI PNXXR analyzes medical images (Chest X-rays) to identify features suggestive of pneumothorax. It does not analyze biological samples from the patient.
- Intended Use: The intended use clearly states it's a "software workflow tool designed to aid the clinical assessment of adult... Chest X-Ray cases". This is image analysis, not in vitro testing.
Therefore, the EFAI PNXXR falls under the category of medical imaging software or a computer-assisted diagnosis (CAD) tool, not an In Vitro Diagnostic device.
No
The letter does not state that the FDA has reviewed and approved or cleared a Predetermined Change Control Plan (PCCP) for this specific device. The section "Control Plan Authorized (PCCP) and relevant text" explicitly states "Not Found".
Intended Use / Indications for Use
EFAI PNXXR is a software workflow tool designed to aid the clinical assessment of adult (22 years of age or older) Posteroanterior (PA) view Chest X-Ray cases with features suggestive of pneumothorax in the medical care environment. EFAI PNXXR analyzes cases using an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. EFAI PNXXR is not intended to direct attention to specific portions or anomalies of an image. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
Product codes (comma separated list FDA assigned to the subject device)
QFM
Device Description
EFAI ChestSuite XR Pneumothorax Assessment System, herein referred to as EFAI PNXXR, is a radiological computer-assisted triage and notification software system. The software uses deep learning techniques to automatically analyze PA chest x-rays and sends notification messages to the picture archiving and communication system (PACS)/workstation to allow suspicious findings of pneumothorax to be identified.
The device is intended to provide a passive notification through the PACS/workstation to the radiologists indicating the existence of a case that may potentially benefit from the prioritization. It does not mark, highlight, or direct users' attention to a specific location on the original chest X-ray. The device aims to aid in prioritization and triage of radiological medical images only.
The deployment environment is recommended to be in a local network with an existing hospitalgrade IT system in place. EFAI PNXXR should be installed on a specialized server supporting deep learning processing. The configurations are only being operated by the manufacturer:
- · Local network setting of input and output destinations;
Mentions image processing
Not Found
Mentions AI, DNN, or ML
EFAI PNXXR analyzes cases using an artificial intelligence algorithm to identify suspected findings.
The software uses deep learning techniques to automatically analyze PA chest x-rays
Input Imaging Modality
Posteroanterior (PA) view Chest X-Ray
Anatomical Site
Chest
Indicated Patient Age Range
adult (22 years of age or older)
Intended User / Care Setting
Hospital networks and trained clinicians
Description of the training set, sample size, data source, and annotation protocol
Neither of the datasets were used as part of the EFAI PNXXR model development or analytical validation testing.
Description of the test set, sample size, data source, and annotation protocol
The standalone dataset consists of 800 anonymized Chest X-ray images consecutively collected from 3 institutions from the US and 1 institution from the OUS. The standalone dataset included pneumothorax positive (n=182) and negative cases (n=618). The cases were acquired from several X-Ray scanner manufacturers, including Samsung Electronics, Shimadzu, Toshiba, Canon Inc., Fujifilm Corporation, GE Healthcare, Konica Minolta, Philips Medical Systems, Swissray, etc. The X-Ray is taken in a standard chest X-ray protocol in PA view. Confounding cases in the dataset include possible confounders as the following: Airspace Disease, Atelectasis, Blebs, Cardiomegaly, Fracture, Infiltrate, Mass, Nodule, Obstructive Airways Disease, Pleural Effusion, Pneumonia, Scoliosis and Image Ouality Issues. Three US board-certified radiologists determined the presence of pneumothorax in each case independently. The reference standard (ground truth) was generated by the majority agreement between the three board-certified radiologists.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
To establish the standalone performance of EFAI PNXXR, a retrospective, blinded, multicenter study was performed to compare the pneumothorax classification performance and processing time of EFAI PNXXR against the predicate device, red dot™ (Behold.AI, K191556). The standalone dataset consists of 800 anonymized Chest X-ray images. The dataset included pneumothorax positive (n=182) and negative cases (n=618).
Summary of results: The dataset included 56.50% males and 43.25% females, and the mean age of cases was 50.2 years. Overall, the EFAI PNXXR was able to demonstrate sensitivity and specificity of 0.97 (95% CI=0.94-0.99) and 0.98 (95% CI=0.96-0.99) respectively, as well as an AUC of 0.99 (95% CI=0.98-1.00), which is substantially equivalent to the predicate device (Behold.ai red dot™ (K191556). The average performance time of the EFAI PNXXR was 23.3 seconds with a 95% CI of [23.2. 23.4] and was comparable with the predicate device, red dot™ (Behold.AI, K191556, 29.3 seconds). The subgroup analysis included gender, age, manufacturer, data source (US and OUS), size and location of pneumothorax, and demonstrated consistent performance for the device across all subgroups.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity: 0.97 (95% CI=0.94-0.99)
Specificity: 0.98 (95% CI=0.96-0.99)
AUC: 0.99 (95% CI=0.98-1.00)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2080 Radiological computer aided triage and notification software.
(a)
Identification. Radiological computer aided triage and notification software is an image processing prescription device intended to aid in prioritization and triage of radiological medical images. The device notifies a designated list of clinicians of the availability of time sensitive radiological medical images for review based on computer aided image analysis of those images performed by the device. The device does not mark, highlight, or direct users' attention to a specific location in the original image. The device does not remove cases from a reading queue. The device operates in parallel with the standard of care, which remains the default option for all cases.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Design verification and validation must include:
(i) A detailed description of the notification and triage algorithms and all underlying image analysis algorithms including, but not limited to, a detailed description of the algorithm inputs and outputs, each major component or block, how the algorithm affects or relates to clinical practice or patient care, and any algorithm limitations.
(ii) A detailed description of pre-specified performance testing protocols and dataset(s) used to assess whether the device will provide effective triage (
e.g., improved time to review of prioritized images for pre-specified clinicians).(iii) Results from performance testing that demonstrate that the device will provide effective triage. The performance assessment must be based on an appropriate measure to estimate the clinical effectiveness. The test dataset must contain sufficient numbers of cases from important cohorts (
e.g., subsets defined by clinically relevant confounders, effect modifiers, associated diseases, and subsets defined by image acquisition characteristics) such that the performance estimates and confidence intervals for these individual subsets can be characterized with the device for the intended use population and imaging equipment.(iv) Stand-alone performance testing protocols and results of the device.
(v) Appropriate software documentation (
e.g., device hazard analysis; software requirements specification document; software design specification document; traceability analysis; description of verification and validation activities including system level test protocol, pass/fail criteria, and results).(2) Labeling must include the following:
(i) A detailed description of the patient population for which the device is indicated for use;
(ii) A detailed description of the intended user and user training that addresses appropriate use protocols for the device;
(iii) Discussion of warnings, precautions, and limitations must include situations in which the device may fail or may not operate at its expected performance level (
e.g., poor image quality for certain subpopulations), as applicable;(iv) A detailed description of compatible imaging hardware, imaging protocols, and requirements for input images;
(v) Device operating instructions; and
(vi) A detailed summary of the performance testing, including: test methods, dataset characteristics, triage effectiveness (
e.g., improved time to review of prioritized images for pre-specified clinicians), diagnostic accuracy of algorithms informing triage decision, and results with associated statistical uncertainty (e.g., confidence intervals), including a summary of subanalyses on case distributions stratified by relevant confounders, such as lesion and organ characteristics, disease stages, and imaging equipment.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Ever Fortune AI Co., Ltd. % Ti-Hao Wang Chief Technology Officer RM.D. 8F, NO. 573, SEC 2, Taiwan Blvd, West Dist. Taichung City, 403020 TAIWAN
November 8, 2022
Re: K221552
Trade/Device Name: EFAI ChestSuite XR Pneumothorax Assessment System Regulation Number: 21 CFR 892.2080 Regulation Name: Radiological Computer Aided Triage And Notification Software Regulatory Class: Class II Product Code: QFM Dated: October 3, 2022 Received: October 4, 2022
Dear Ti-Hao Wang:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
1
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Jessica Lamb
Jessica Lamb, Ph.D. Assistant Director Imaging Software Team DHT8B: Division of Radiological Imaging Devices and Electronic Products OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Image /page/2/Picture/0 description: The image shows the logo for Ever Fortune AI. The logo consists of a stylized human figure with a green globe on top, followed by the text "EVER" on the top line and "FORTUNE.AI" on the bottom line. The text and the human figure are in a matching teal color.
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
510(k) Number (if known) K221552
Device Name EFAI Chestsuite XR Pneumothorax Assessment System
Indications for Use (Describe)
EFAI PNXXR is a software workflow tool designed to aid the clinical assessment of adult (22 years of age or older) Posteroanterior (PA) view Chest X-Ray cases with features suggestive of pneumothorax in the medical care environment. EFAI PNXXR analyzes cases using an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. EFAI PNXXR is not intended to direct attention to specific portions or anomalies of an image. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | |
|---|---|
| Over |
ver-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (6/20)
Page 1 of 1
PSC Publishing Services (301) 443-6740 EF
3
510(k) Summary
1. General Information
| 510(k) Sponsor | Ever Fortune.AI Co., Ltd. |
|---|---|
| Address | Rm. D, 8F. No. 573, Sec. 2 Taiwan Blvd. |
| West Dist. | |
| Taichung City 403020 | |
| TAIWAN | |
| Applicant | Joseph Chang |
| Contact Information | 886-04-23213838 #216 |
| joseph.chang@everfortune.ai | |
| Correspondence Person | Ti-Hao Wang, MD |
| Contact Information | 886-04-23213838 #168 |
| tihao.wang@everfortune.ai | |
| Date Prepared | May 31, 2022 |
2. Proposed Device
| Proprietary Name | EFAI ChestSuite XR Pneumothorax Assessment System v1.0 |
|---|---|
| Common Name | EFAI PNXXR v1.0 |
| Classification Name | Radiological Computer-Assisted Prioritization Software For Lesions |
| Regulation Number | 21 CFR 892.2080 |
| Regulation Name | Radiological Computer Aided Triage and Notification Software |
| Product Code | QFM |
| Regulatory Class | II |
3. Predicate Device
| Proprietary Name | red dot™ |
|---|---|
| Premarket Notification | K191556 |
| Classification Name | Radiological Computer-Assisted Prioritization Software For Lesions |
| Regulation Number | 21 CFR 892.2080 |
| Regulation Name | Radiological Computer Aided Triage and Notification Software |
| Product Code | QFM |
| Regulatory Class | II |
4
4. Device Description
EFAI ChestSuite XR Pneumothorax Assessment System, herein referred to as EFAI PNXXR, is a radiological computer-assisted triage and notification software system. The software uses deep learning techniques to automatically analyze PA chest x-rays and sends notification messages to the picture archiving and communication system (PACS)/workstation to allow suspicious findings of pneumothorax to be identified.
The device is intended to provide a passive notification through the PACS/workstation to the radiologists indicating the existence of a case that may potentially benefit from the prioritization. It does not mark, highlight, or direct users' attention to a specific location on the original chest X-ray. The device aims to aid in prioritization and triage of radiological medical images only.
The deployment environment is recommended to be in a local network with an existing hospitalgrade IT system in place. EFAI PNXXR should be installed on a specialized server supporting deep learning processing. The configurations are only being operated by the manufacturer:
- · Local network setting of input and output destinations;
5. Intended Use / Indications for Use
EFAI PNXXR is a software workflow tool designed to aid the clinical assessment of adult (22 years of age or older) Posteroanterior (PA) view Chest X-Ray cases with features suggestive of pneumothorax in the medical care environment. EFAI PNXXR analyzes cases using an artificial intelligence algorithm to identify suspected findings. It makes case-level output available to a PACS/workstation for worklist prioritization or triage. EFAI PNXXR is not intended to direct attention to specific portions or anomalies of an image. Its results are not intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out pneumothorax or otherwise preclude clinical assessment of X-Ray cases.
5
6. Comparison of Technological Characteristics with Predicate Device
Table below provides a comparison of the intended use and key technological features of EFAI PNXXR with that of the Primary Predicate, red dot™ (K191556).
| | Ever Fortune.AI Co., Ltd.
(EFAI) | Behold.AI Technologies Limited | Supported Modalities | X-Ray (PA view) | X-Ray (PA or AP view) |
|------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|
| Company | | | Body Part | Chest | Chest |
| Device Name | EFAI PNXXR | red dot™ | Artificial Intelligence
Algorithm | Yes | Yes |
| 510k Number | K221552 | K191556 | Limited to analysis of
imaging data | Yes | Yes |
| Regulation No. | 21CFR 892.2080 | 21CFR 892.2080 | Aids prompt
identification of cases
with indicated
findings | Yes | Yes |
| Classification | II | II | Image Input | DICOM | DICOM |
| Product Code | QFM | QFM | Identify patients
with a pre-specified
clinical condition | Yes | Yes |
| Intended
Use/Indication for
Use | EFAI PNXXR is a software
workflow tool designed to aid
the clinical assessment of adult
(22 years of age or older)
Posteroanterior (PA) view Chest
X-Ray cases with features
suggestive of pneumothorax in
the medical care environment.
EFAI PNXXR analyzes cases
using an artificial intelligence
algorithm to identify suspected
findings. It makes case-level
output available to a
PACS/workstation for worklist
prioritization or triage. EFAI
PNXXR is not intended to direct
attention to specific portions or
anomalies of an image. Its
results are not intended to be
used on a stand-alone basis for
clinical decision-making nor is
| The red dot™ software platform
is a software workflow tool
designed to aid the clinical
assessment of adult Chest X-Ray
cases with features suggestive of
Pneumothorax in the medical
care environment. red dot™
analyzes cases using an artificial
intelligence algorithm to identify
suspected findings. It makes
case-level output available to a
PACS/workstation for worklist
prioritization or triage. red dot™
is not intended to direct attention
to specific portions of an image
or to anomalies other than
Pneumothorax. Its results are not
intended to be used on a stand-alone basis for clinical decision-making nor is it intended to rule out Pneumothorax or otherwise preclude clinical assessment of X-Ray cases. | Clinical condition | Pneumothorax | Pneumothorax |
| Intended user | Hospital networks and trained
clinicians | Hospital networks and trained
clinicians | Alert to finding | Passive notification flagged for
review | Passive notification flagged for
review |
| Independent of
standard of care
workflow | Yes; No cases are removed
from worklist | Yes; No cases are removed from
worklist | | | |
| Where results are
received | PACS / RIS / EPR
/Workstation | PACS / RIS / EPR / Workstation | | | |
Table - Comparison with the Predicate Device.
6
The proposed device, EFAI PNXXR, is substantially equivalent to the claimed predicate, red dot™ (K191556).
7
7. Performance Data
Performance of the EFAI PNXXR v1.0 has been evaluated and verified in accordance with software specifications and applicable performance standards through software verification and validation testing. Additionally, the software validation activities were performed in accordance with IEC 62304:2006/A1:2016 - Medical device software – Software life cvcle processes, in addition to the FDA Guidance documents, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices"(2005), and "Content of Premarket Submission for Management of Cybersecurity in Medical Devices."
To establish the standalone performance of EFAI PNXXR, a retrospective, blinded, multicenter study was performed to compare the pneumothorax classification performance and processing time of EFAI PNXXR against the predicate device, red dot™ (Behold.AI, K191556). The standalone dataset consists of 800 anonymized Chest X-ray images consecutively collected from 3 institutions from the US and 1 institution from the OUS. Neither of the datasets were used as part of the EFAI PNXXR model development or analytical validation testing.
The standalone dataset included pneumothorax positive (n=182) and negative cases (n=618). The cases were acquired from several X-Ray scanner manufacturers, including Samsung Electronics, Shimadzu, Toshiba, Canon Inc., Fujifilm Corporation, GE Healthcare, Konica Minolta, Philips Medical Systems, Swissray, etc. The X-Ray is taken in a standard chest X-ray protocol in PA view. Confounding cases in the dataset include possible confounders as the following: Airspace Disease, Atelectasis, Blebs, Cardiomegaly, Fracture, Infiltrate, Mass, Nodule, Obstructive Airways Disease, Pleural Effusion, Pneumonia, Scoliosis and Image Ouality Issues.
Three US board-certified radiologists determined the presence of pneumothorax in each case independently. The reference standard (ground truth) was generated by the majority agreement between the three board-certified radiologists. The performance acceptance criteria were set such that the lower bounds of 95% confidence intervals of both sensitivity and specificity should exceed 0.8. Summary of results: The dataset included 56.50% males and 43.25% females, and the mean age of cases was 50.2 years. Overall, the EFAI PNXXR was able to demonstrate sensitivity and specificity of 0.97 (95% CI=0.94-0.99) and 0.98 (95% CI=0.96-0.99) respectively, as well as an AUC of 0.99 (95% CI=0.98-1.00), which is substantially equivalent to the predicate device (Behold.ai red dot™ (K191556). The average performance time of the EFAI PNXXR was 23.3 seconds with a 95% CI of [23.2. 23.4] and was comparable with the predicate device, red dot™ (Behold.AI, K191556, 29.3 seconds). The subgroup analysis included gender, age, manufacturer, data source (US and OUS), size and location of pneumothorax, and demonstrated consistent performance for the device across all subgroups.
The table below provides a more detailed description of the performance across different manufacturers.
8
| Manufacturer | EFAI PNXXR | |
|---|---|---|
| Sensitivity | ||
| (95% Wilson CI) | Specificity | |
| (95% Wilson CI) | ||
| Samsung Electronics | 1.00 (0.86, 1.00] | 0.99 (0.97, 1.00) |
| Shimadzu | 0.98 (0.91, 1.00) | 0.99 (0.95, 1.00) |
| Toshiba | 1.00 (0.90, 1.00] | 0.99 (0.95, 1.00) |
| Others a, b | 0.94 (0.85, 0.97) | 0.81 (0.66, 0.91) |
Table. Sensitivity and specificity of EFAI PNXXR by manufacturer
ª Other X-ray manufacturers include Canon Inc., Fujifilm Corporation, GE Healthcare, Konica Minolta, Philips Medical Systems, Swissray, etc.
b Manufacturers are merged into the category "Others" if the number of cases or PNX Cases or PNX Cases) were less than or equal to five in the study.
We also evaluated cases with image quality issues or radiologic findings other than pneumothorax, to see if these possible confounders systematically affect the software's performance. We found the device performs consistently and reliably under these circumstances. The results demonstrate that the EFAI PNXXR device is as safe and effective as the predicate device red dot™.
8. Conclusion
Based on the information submitted in this premarket notification, and based on the indications for use, technological characteristics, and performance testing, the EFAI PNXXR v1.0 raises no new questions of safety and effectiveness and is substantially equivalent to the predicate device in terms of safety, effectiveness, and performance.